Document Detail


Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.
MedLine Citation:
PMID:  23287454     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The development of drugs that inhibit platelets has been driven by a combination of clinical insights, fundamental science, and sheer luck. The process has evolved as the days of stumbling on therapeutic gems, such as aspirin, have long passed and have been replaced by an arduous process in which a drug is designed to target a specific protein implicated in a well-characterized pathophysiological process, or so we would like to believe. The development of antiplatelet therapy illustrates the importance of understanding the mechanisms of disease and the pharmacology of the compounds we develop, coupled with careful clinical experimentation and observation and, yes, still, a fair bit of luck.
Authors:
Desmond J Fitzgerald; Garret A Fitzgerald
Related Documents :
7970004 - The clinical efficacy of lamotrigine as an antiepileptic drug.
16599284 - Effect of levetiracetam on truncal tic in neuroacanthocytosis.
24454 - The extraction of antiepileptic drugs. model study on partition coefficients.
12891224 - Pharmacokinetic drug interactions in children taking oxcarbazepine.
15051054 - New chemical adaptor unit designed to release a drug from a tumor targeting device by e...
21948264 - Synergistic effects of combination with fludarabine and carboplatin depend on fludarabi...
Publication Detail:
Type:  Historical Article; Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Circulation research     Volume:  112     ISSN:  1524-4571     ISO Abbreviation:  Circ. Res.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-04     Completed Date:  2013-02-27     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  0047103     Medline TA:  Circ Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  174-94     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Aspirin / therapeutic use
Blood Platelets / drug effects*,  enzymology
Cardiovascular Diseases / blood,  drug therapy*,  history
Cyclooxygenase Inhibitors / administration & dosage,  adverse effects,  history,  therapeutic use*
Dose-Response Relationship, Drug
Drug Discovery* / history
Drug Resistance
Evidence-Based Medicine
History, 20th Century
History, 21st Century
Humans
Pharmacogenetics
Platelet Aggregation Inhibitors / administration & dosage,  adverse effects,  history,  therapeutic use*
Purinergic P2Y Receptor Antagonists / administration & dosage,  adverse effects,  history,  therapeutic use*
Ticlopidine / analogs & derivatives,  therapeutic use
Translational Medical Research* / history
Grant Support
ID/Acronym/Agency:
HL062250/HL/NHLBI NIH HHS; U54 HL117798/HL/NHLBI NIH HHS; U54HL117798/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Cyclooxygenase Inhibitors; 0/Platelet Aggregation Inhibitors; 0/Purinergic P2Y Receptor Antagonists; A74586SNO7/clopidogrel; OM90ZUW7M1/Ticlopidine; R16CO5Y76E/Aspirin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An electrophysiological investigation of non-symbolic magnitude processing: Numerical distance effec...
Next Document:  Membrane-associated matrix proteolysis and heart failure.